Difference between revisions of "Resource:9736d9b3-fbe1-45cf-a5d0-20e19038d394"
From The Embassy of Good Science
Marc.VanHoof (talk | contribs) |
Marc.VanHoof (talk | contribs) |
||
| Line 1: | Line 1: | ||
{{Resource | {{Resource | ||
|Resource Type=Cases | |Resource Type=Cases | ||
| − | |Title=Guest | + | |Title=Guest Authorship, Mortality Reporting, and Integrity in Rofecoxib Studies |
| − | |Is About=The study by Drs | + | |Is About=The study by Drs X and Y and the accompanying Editorial by Drs Z and Q regarding rofecoxib illustrate the recurring problem of discretionary or data-driven analysis<ref>FitzGerald, Garret A. "Guest authorship, mortality reporting, and integrity in rofecoxib studies." ''JAMA'' 300.8 (2008): 900-906.</ref> This is a facutal case. |
| − | |Important Because=Given the possibility of selective analysis based on observed data and the risk of positive results due to chance alone, it is critical to know in detail which analyses were prespecified and when the prespecification occurred<ref> | + | <references /> |
| − | + | |Important Because=Given the possibility of selective analysis based on observed data and the risk of positive results due to chance alone, it is critical to know in detail which analyses were prespecified and when the prespecification occurred<ref>FitzGerald, Garret A. "Guest authorship, mortality reporting, and integrity in rofecoxib studies." ''JAMA'' 300.8 (2008): 900-906.</ref>. | |
| − | + | <references /> | |
| − | |||
| − | |||
| − | |||
| − | |||
|Important For=Researchers | |Important For=Researchers | ||
}} | }} | ||
| Line 15: | Line 11: | ||
|Has Link=https://jamanetwork.com/journals/jama/article-abstract/182444 | |Has Link=https://jamanetwork.com/journals/jama/article-abstract/182444 | ||
}} | }} | ||
| − | {{Related To}} | + | {{Related To |
| + | |Related To Theme=Theme:Cbe88760-7f0e-4d6d-952b-b724bb0f375e | ||
| + | }} | ||
{{Tags | {{Tags | ||
|Involves=Drs Psaty; Kronmal | |Involves=Drs Psaty; Kronmal | ||
Revision as of 16:27, 26 May 2020
ResourcesCases
Guest Authorship, Mortality Reporting, and Integrity in Rofecoxib Studies
What is this about?
The study by Drs X and Y and the accompanying Editorial by Drs Z and Q regarding rofecoxib illustrate the recurring problem of discretionary or data-driven analysis[1] This is a facutal case.
- ↑ FitzGerald, Garret A. "Guest authorship, mortality reporting, and integrity in rofecoxib studies." JAMA 300.8 (2008): 900-906.
Why is this important?
Given the possibility of selective analysis based on observed data and the risk of positive results due to chance alone, it is critical to know in detail which analyses were prespecified and when the prespecification occurred[1].
- ↑ FitzGerald, Garret A. "Guest authorship, mortality reporting, and integrity in rofecoxib studies." JAMA 300.8 (2008): 900-906.
